Crossmark

Intravenously administered interleukin-7 to reverse lymphopenia in patients with septic shock: a double-blind, randomized, placebo-controlled trial

Crossref DOI link: https://doi.org/10.1186/s13613-023-01109-w

Published Print: 2023

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Daix, Thomas

Mathonnet, Armelle

Brakenridge, Scott

Dequin, Pierre-François

Mira, Jean-Paul

Berbille, Frederique

Morre, Michel

Jeannet, Robin

Blood, Teresa

Unsinger, Jacqueline

Blood, Jane

Walton, Andrew

Moldawer, Lyle L.

Hotchkiss, Richard

François, Bruno https://orcid.org/0000-0002-2531-1652
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct03821038 at ClinicalTrials.gov

Documents that mention this clinical trial

Intravenously administered interleukin-7 to reverse lymphopenia in patients with septic shock: a double-blind, randomized, placebo-controlled trial
https://doi.org/10.1186/s13613-023-01109-w
License Information

Text and Data Mining valid from 2023-01-01

Text and Data Mining valid from 2023-01-01

Version of Record valid from 2025-11-19
More Information

This article is maintained by: Elsevier

Article Title: Intravenously administered interleukin-7 to reverse lymphopenia in patients with septic shock: a double-blind, randomized, placebo-controlled trial

Journal Title: Annals of Intensive Care

CrossRef DOI link to publisher maintained version: https://doi.org/10.1186/s13613-023-01109-w

Content Type: article

Copyright: Copyright © 2023 The Author(s) 2023. Published by Elsevier Masson SAS